In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quartet Medicine Inc.

www.quartetmedicine.com

Latest From Quartet Medicine Inc.

Execs On The Move, September 2016

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

Biopharma Quarterly Dealmaking Statistics, Q1 2016

Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.

BioPharmaceutical Deals

Start-Up Previews, April 2016

In this month's issue of Start-Up, we profile Cenna Biosciences, Entac Medical, Hemovent, MediBeacon and Quartet Medicine.

BioPharmaceutical Medical Device

Quartet Medicine Inc.

Quartet Medicine Inc.'s pipeline of novel small-molecule drugs to address chronic pain and inflammation target the tetrahydrobiopterin (BH4) synthesis pathway, a target with genetic and pharmacological links to regulating human disease at the intersection of the peripheral nervous system and the immune system. The start-up thinks its approach has the potential to provide improved efficacy without the side effects associated with existing centrally acting analgesics.

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Quartet Medicine Inc.
  • Senior Management
  • Gerhard Koenig, PhD, CEO
  • Contact Info
  • Quartet Medicine Inc.
    Phone: (617) 588-2665
    400 Technology Sq.
    Floor 10
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register